Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE)
The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the end of 2032.
HAE or SYK: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
Are Investors Undervaluing Haemonetics (HAE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 27.8% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025.
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Here's Why Haemonetics (HAE) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wall Street Analysts Think Haemonetics (HAE) Could Surge 25.58%: Read This Before Placing a Bet
The mean of analysts' price targets for Haemonetics (HAE) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.
Compared to Estimates, Haemonetics (HAE) Q2 Earnings: A Look at Key Metrics
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Haemonetics (HAE) Tops Q2 Earnings and Revenue Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.99 per share a year ago.
